View ValuationIntegraGen 将来の成長Future 基準チェック /06現在、 IntegraGenの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Jul 02IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025IntegraGen SA omits to maintain revenue guidance for the full year of 2025. For the period, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the company is not maintaining its revenue growth forecasts for 2025.すべての更新を表示Recent updatesお知らせ • May 14IntegraGen SA, Annual General Meeting, May 13, 2026IntegraGen SA, Annual General Meeting, May 13, 2026. Location: evry FranceReported Earnings • Apr 28Full year 2025 earnings releasedFull year 2025 results: Revenue: €5.33m (down 39% from FY 2024). Net loss: €2.66m (loss widened €2.41m from FY 2024).New Risk • Nov 03New major risk - Revenue and earnings growthEarnings have declined by 30% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (€999.7k market cap, or US$1.15m).Board Change • Oct 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Francois Fontaine was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 02IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025IntegraGen SA omits to maintain revenue guidance for the full year of 2025. For the period, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the company is not maintaining its revenue growth forecasts for 2025.お知らせ • May 16IntegraGen SA, Annual General Meeting, Jun 19, 2025IntegraGen SA, Annual General Meeting, Jun 19, 2025. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry FranceNew Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€3.58m market cap, or US$3.75m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€3.11m market cap, or US$3.27m). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change).New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (€4.20m market cap, or US$4.49m).お知らせ • May 17IntegraGen SA, Annual General Meeting, Jun 20, 2024IntegraGen SA, Annual General Meeting, Jun 20, 2024. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry FranceReported Earnings • May 06Full year 2023 earnings releasedFull year 2023 results: Revenue: €12.8m (down 2.9% from FY 2022). Net loss: €171.4k (loss widened €167.9k from FY 2022).New Risk • Feb 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€5.50m market cap, or US$5.94m). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).お知らせ • Jan 17IntegraGen SA to Report Fiscal Year 2023 Results on Apr 24, 2024IntegraGen SA announced that they will report fiscal year 2023 results on Apr 24, 2024New Risk • Oct 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€6.32m market cap, or US$6.69m). Minor Risk Share price has been volatile over the past 3 months (6.3% average weekly change).お知らせ • Jan 11+ 1 more updateIntegraGen SA to Report Fiscal Year 2022 Results on Apr 24, 2023IntegraGen SA announced that they will report fiscal year 2022 results on Apr 24, 2023Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.32, the stock trades at a trailing P/E ratio of 31.8x. Average trailing P/E is 29x in the Biotechs industry in Europe.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 20First half 2022 earnings releasedFirst half 2022 results: Revenue: €6.76m (up 34% from 1H 2021). Net loss: €141.0k (loss narrowed 66% from 1H 2021).お知らせ • May 18IntegraGen SA to Report First Half, 2022 Results on Oct 18, 2022IntegraGen SA announced that they will report first half, 2022 results on Oct 18, 2022Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、IntegraGen は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BST:7N8 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20255-3-2-2N/A9/30/20256-2N/AN/AN/A6/30/20257-2N/AN/AN/A3/31/20258-1N/AN/AN/A12/31/202490N/AN/AN/A9/30/2024100N/AN/AN/A6/30/2024110N/AN/AN/A3/31/2024120N/AN/AN/A12/31/2023130N/AN/AN/A9/30/2023130N/AN/AN/A6/30/2023130N/AN/AN/A3/31/2023130N/AN/AN/A12/31/2022130N/AN/AN/A9/30/2022130N/AN/AN/A6/30/2022130N/AN/AN/A3/31/2022120N/AN/AN/A12/31/2021110N/AN/AN/A9/30/2021100N/AN/AN/A6/30/20219-1N/AN/AN/A3/31/20219-1N/AN/AN/A12/31/202090N/AN/AN/A9/30/202090N/AN/AN/A6/30/202090N/AN/AN/A3/31/202090N/AN/AN/A12/31/201980N/AN/AN/A9/30/20198-1N/AN/AN/A6/30/20197-1N/AN/AN/A3/31/20197-1N/AN/AN/A12/31/20187-1N/AN/AN/A9/30/20187-1N/AN/AN/A6/30/20187-1N/AN/AN/A3/31/20187-1N/AN/AN/A12/31/20177-1N/AN/AN/A9/30/20176-1N/AN/AN/A6/30/20177-1N/AN/AN/A3/31/20176-1N/AN/AN/A12/31/20166-2N/AN/AN/A9/30/20166-2N/AN/AN/A6/30/20166-2N/AN/AN/A3/31/20166-2N/AN/AN/A12/31/20156-2N/AN/AN/A9/30/20156-1N/AN/AN/A6/30/20156-1N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 7N8の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 7N8の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 7N8の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 7N8の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 7N8の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 7N8の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 04:50終値2026/06/18 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IntegraGen SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Arnaud GuérinPortzamparc BNP Paribas
お知らせ • Jul 02IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025IntegraGen SA omits to maintain revenue guidance for the full year of 2025. For the period, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the company is not maintaining its revenue growth forecasts for 2025.
お知らせ • May 14IntegraGen SA, Annual General Meeting, May 13, 2026IntegraGen SA, Annual General Meeting, May 13, 2026. Location: evry France
Reported Earnings • Apr 28Full year 2025 earnings releasedFull year 2025 results: Revenue: €5.33m (down 39% from FY 2024). Net loss: €2.66m (loss widened €2.41m from FY 2024).
New Risk • Nov 03New major risk - Revenue and earnings growthEarnings have declined by 30% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (€999.7k market cap, or US$1.15m).
Board Change • Oct 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Francois Fontaine was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 02IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025IntegraGen SA omits to maintain revenue guidance for the full year of 2025. For the period, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the company is not maintaining its revenue growth forecasts for 2025.
お知らせ • May 16IntegraGen SA, Annual General Meeting, Jun 19, 2025IntegraGen SA, Annual General Meeting, Jun 19, 2025. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry France
New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€3.58m market cap, or US$3.75m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€3.11m market cap, or US$3.27m). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change).
New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (€4.20m market cap, or US$4.49m).
お知らせ • May 17IntegraGen SA, Annual General Meeting, Jun 20, 2024IntegraGen SA, Annual General Meeting, Jun 20, 2024. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry France
Reported Earnings • May 06Full year 2023 earnings releasedFull year 2023 results: Revenue: €12.8m (down 2.9% from FY 2022). Net loss: €171.4k (loss widened €167.9k from FY 2022).
New Risk • Feb 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€5.50m market cap, or US$5.94m). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).
お知らせ • Jan 17IntegraGen SA to Report Fiscal Year 2023 Results on Apr 24, 2024IntegraGen SA announced that they will report fiscal year 2023 results on Apr 24, 2024
New Risk • Oct 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€6.32m market cap, or US$6.69m). Minor Risk Share price has been volatile over the past 3 months (6.3% average weekly change).
お知らせ • Jan 11+ 1 more updateIntegraGen SA to Report Fiscal Year 2022 Results on Apr 24, 2023IntegraGen SA announced that they will report fiscal year 2022 results on Apr 24, 2023
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.32, the stock trades at a trailing P/E ratio of 31.8x. Average trailing P/E is 29x in the Biotechs industry in Europe.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 20First half 2022 earnings releasedFirst half 2022 results: Revenue: €6.76m (up 34% from 1H 2021). Net loss: €141.0k (loss narrowed 66% from 1H 2021).
お知らせ • May 18IntegraGen SA to Report First Half, 2022 Results on Oct 18, 2022IntegraGen SA announced that they will report first half, 2022 results on Oct 18, 2022
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.